COMPARATIVE OUTCOMES BETWEEN NEWER AND OLDER SURGERIES FOR GLAUCOMA

BY Sameh Mosaed MD*, Laurie Dustin MS, AND Don S. Minckler MD MS

ABSTRACT

Purpose: To compare outcomes across Trabectome, iScience (canaloplasty), trabeculectomy, and aqueous shunts regarding intraocular pressure (IOP), adjunctive medications, and complications after glaucoma-only and combined glaucoma-phacoemulsification surgeries for open-angle glaucomas.

Method: A literature review compares success rates, complications, efficacy, and limitations of traditional and novel glaucoma surgical procedures.

Results: Trabectome and canaloplasty provide modest IOP reduction with minimal intraoperative or postoperative complications. Results of Baerveldt glaucoma implant IOP reduction are comparable to trabeculectomy, but typically this shunt requires more postoperative IOP-lowering medication to achieve a success rate comparable to trabeculectomy.

Conclusion: Trabeculectomy is still the most effective IOP-lowering procedure performed today but continues to have the highest serious complication rates. Trabectome and canaloplasty are reasonable surgical therapy choices for patients in which IOPs in the mid-teens seem adequate.

INTRODUCTION

Trabeculectomy (traditional glaucoma filtering surgery) is frequently accompanied by numerous short- and long-term complications. These include hypotony, bleb leaks, late blebitis, accelerated cataract progression, choroidal effusions and hemorrhage, and prolonged or permanent visual impairment from hypotony maculopathy. These complications are increased when antifibrotics are used; however, without antifibrotics, trabeculectomy has a relatively high short-term failure rate.1-3 Outcomes of primary trabeculectomy with and without antifibrotics have been compared to medical therapy in the Collaborative Initial Glaucoma Treatment Study (CIGTS).4 Results from that trial indicated that primary trabeculectomy with or without antifibrotics was equivalent to medical therapy for open-angle glaucoma through 5 years of follow-up, with intraocular pressures (IOPs) comparable to those after newer surgical procedures, such as the Trabectome and canaloplasty. Although trabeculectomy provided lower IOPs than laser and medical therapy in the CIGTS, the visual field outcomes were judged to be equivalent. The Fluorouracil Filtering Surgery Study and the ongoing Tube vs Trabeculectomy (TVT) study have provided valid data on trabeculectomy outcomes with antifibrotics in eyes with prior cataract surgery or failed prior filters, with IOP outcomes averaging 14 mm Hg, about 25% lower than reported for newer procedures.5,6 Several novel glaucoma procedures have recently been published or presented, including Trabectome (NeoMedix Corporation, Tustin, California), canaloplasty (iScience Interventional, Menlo Park, California), iStent (Glaukos Corporation, Laguna Hills, California), and a gold suprachoroidal shunt (Solvex, Inc, Medway, Massachusetts).7 At this time, published literature is available for clinical outcome data only on Trabectome and canaloplasty.7-11 This report aims to contrast the rationales, published procedures performed, success rates, efficacies, surgical complexities, and complications across these two new procedures compared to trabeculectomy and aqueous shunts. We also suggest that ongoing publications should record specific parameters to facilitate future comparisons among these procedures.

METHODS

A literature review of relevant peer-reviewed publications was undertaken. Outcomes among reported cases were tabulated, including success rates, percent IOP lowering, complications, and medication reliance postoperatively for Trabectome, canaloplasty, trabeculectomy, and Baerveldt glaucoma implant surgeries in which at least 1-year follow-up was reported. Minckler and colleagues9 presented the 3-year results of a retrospective Trabectome case series at multiple sites in the United States and a single site in Mexico at the American Ophthalmological Society (AOS) meeting in 2008. These results were reanalyzed for this report to summarize Trabectome outcomes at 1 year. Canaloplasty 1-year interim results were recently published from a prospective, open-label study at 14 clinical sites in the United States and Germany by Lewis and colleagues10,11 and were analyzed for comparative outcomes. The ongoing TVT study results at 1 year were used for comparison of 1-year outcomes of canaloplasty and Trabeculectome to trabeculectomy and the Baerveldt glaucoma drainage device.6 Statistical analysis for the update of Trabectome outcomes was identical to those previously reported, including survival curves.9

RESULTS

The average preoperative IOP, 12-month postoperative IOP, and number of glaucoma medications at baseline and 12 months following surgery for Trabectome, canaloplasty, trabeculectomy with mitomycin C and Baerveldt glaucoma drainage device are summarized in Table 1. The mean preoperative IOPs for all groups were similar in the mid-20s. The 12-month postoperative IOPs for
the Trabectome group and canaloplasty group were comparable at approximately 16 mm Hg, whereas the IOPs of the trabeculectomy and tube groups were significantly lower at approximately 12 mm Hg. The tube group required more medications to maintain this low IOP as compared to the trabeculectomy group.

### TABLE 1. INTRAOCULAR PRESSURE (IOP) AND MEDICATION USE BEFORE AND 12 MONTHS AFTER GLAUCOMA PROCEDURES

<table>
<thead>
<tr>
<th>PROCEDURE</th>
<th>N</th>
<th>IOP (mm Hg) PREOP</th>
<th>12 mo POSTOP</th>
<th>NO. OF MEDICATIONS PREOP</th>
<th>12 mo POSTOP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canaloplasty only</td>
<td>35</td>
<td>24.1 ± 3.9</td>
<td>16.2 ± 3.5</td>
<td>1.9 ± 1.0</td>
<td>0.6 ± 0.9</td>
</tr>
<tr>
<td>Trabectome only</td>
<td>102</td>
<td>25.7 ± 7.7</td>
<td>16.1 ± 3.0</td>
<td>2.93 ± 1.29</td>
<td>1.50 ± 1.27</td>
</tr>
<tr>
<td>Trabeculectomy</td>
<td>105</td>
<td>25.6 ± 5.3</td>
<td>12.7 ± 5.8</td>
<td>3.0 ± 1.2</td>
<td>0.5 ± 0.9</td>
</tr>
<tr>
<td>Baerveldt implant</td>
<td>107</td>
<td>25.1 ± 5.3</td>
<td>12.4 ± 3.9</td>
<td>3.2 ± 1.1</td>
<td>1.3 ± 1.3</td>
</tr>
</tbody>
</table>

The success rates of the 4 procedures at 12 months postoperatively are summarized in Table 2. The literature reviewed for the canaloplasty procedure did not offer a success rate for canaloplasty as a single procedure, but rather included combined canaloplasty and phacoemulsification procedures as well. The highest success rate of the 4 procedures was quoted for the tube shunt, which had a 96% success at 1 year postoperatively. The definition of success varied between the groups and is listed in Table 2.

### TABLE 2. QUALIFIED SUCCESS RATE ONE YEAR POSTOPERATIVELY FOR FOUR GLAUCOMA PROCEDURES

<table>
<thead>
<tr>
<th>PROCEDURE</th>
<th>DEFINITIONS OF QUALIFIED SUCCESS</th>
<th>SUCCESS RATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canaloplasty only</td>
<td>Percentage of patients at or below target values of 21, 18, and 15 mm Hg at 3, 6, and 12 months, respectively</td>
<td>Not reported</td>
</tr>
<tr>
<td>Trabectome only</td>
<td>No additional glaucoma surgery (1268 of 1415 with no additional glaucoma procedures over 5 years follow-up) (Source: company database 4/7/09) Kaplan-Meier survival analysis at 1 year (Trabectome-only; Figure 5): Failure = IOP &gt;21 or not reduced by 20% below baseline on 2 consecutive visits after 3 months follow-up and no additional glaucoma surgery</td>
<td>89.6%</td>
</tr>
<tr>
<td></td>
<td>Kaplan-Meier survival analysis at 1 year (combined Trabectome-phacoemulsification; Figure 6): Failure = IOP &gt; 21 or not reduced by 20% below baseline on 2 consecutive visits after 3 months follow-up and no additional glaucoma surgery</td>
<td>55%</td>
</tr>
<tr>
<td>Trabeculectomy</td>
<td>IOP &lt;21 mm Hg and &gt;20% below baseline on 2 consecutive follow-up visits, and no additional glaucoma surgery</td>
<td>86.5%</td>
</tr>
<tr>
<td>Baerveldt aqueous</td>
<td>IOP &lt;21 mm Hg and &gt;20% below baseline on 2 consecutive follow-up visits, and no additional glaucoma surgery</td>
<td>96%</td>
</tr>
</tbody>
</table>

IOP, intraocular pressure.

*Patients on or off medications and no additional surgery.

As an update to the Trabectome presentation at the 2008 AOS meeting, the 5-year IOP results compared to mean preoperative IOP for Trabectome-only cases are summarized in Figure 1. This analysis suggests that the IOP-lowering effect of the procedure appears to be sustained at 5 years postoperatively and stabilizes typically in the mid-teens, with the use of fewer IOP-lowering medications, as is illustrated in Figure 2. Average IOP-lowering medication use was reduced from approximately 2.5 medications to approximately one medication at 5 years postoperatively. The medication reliance and IOP-lowering effect of combined Trabectome-phacoemulsification cases also appeared to be sustained at 5 years (Figures 3 and 4).
Kaplan-Meier survival analyses for Trabectome-only surgeries and combined Trabectome-phacoemulsification procedures were performed and are shown in Figures 5 and 6, respectively. For these analyses, failure was defined as IOP of greater than 21 mm Hg and not reduced by 20% from preoperative levels in two consecutive visits after 3 months of follow-up or secondary glaucoma surgery.

**FIGURE 1**
Intraocular pressure (IOP) during 5-year follow-up in Trabectome-only cases (N = 1287).

**FIGURE 2**
Adjunctive medication use during 5-year follow-up in Trabectome-only cases (N = 1287).
Outcomes of Newer and Older Glaucoma Surgery

**FIGURE 3**
Intraocular pressure (IOP) during 5-year follow-up in Trabectome-phacoemulsification cases (N = 687).

**FIGURE 4**
Adjunctive medication use during 5-year follow-up in Trabectome-phacoemulsification cases (N = 687)
**FIGURE 5**
Survival curve for Trabectome-only cases (N = 1287).

**FIGURE 6**
Survival curve for combined Trabectome-phacoemulsification cases (N = 687).
TRABECTOME

The Trabectome surgical device was cleared by the US Food and Drug Administration in January 2004 for the treatment of adult and juvenile open-angle glaucoma. The concept is similar in principle to ab interno trabeculotomy, the key difference being that a microelectrocautery device is used to ablate a strip of the trabecular meshwork and inner wall of Schlemm’s canal, thus allowing direct access of aqueous to the collector channels. This theoretically bypasses the main site of resistance to aqueous outflow and reestablishes the natural drainage passageway out of the eye. Briefly, a 1.7-mm clear corneal incision is made temporally, through which the electrosurgical handpiece is inserted and advanced to the nasal angle under gonioscopic visualization. The tip of the device is inserted into Schlemm’s canal through the trabecular meshwork, and the cautery is then activated via a foot pedal. The handpiece is advanced while cautery is activated to an arc of the meshwork, exposing the back wall of Schlemm’s canal, usually for 90° to 120°. A modified Swan-Jacob goniolens (Ocular Instruments Inc, Bellevue, Washington) was developed for this procedure. The handpiece is then removed, and a single 10-0 suture is placed through the incision. This procedure has also been combined with microincisional phacoemulsification, and the IOP-lowering effect of the combined procedure has been previously reported to be 30% at 1 year in a study of 304 consecutive eyes.8,9

The main complication reported in the use of the Trabectome is transient hyphema (79% to 100%). There have been no reports of choroidal effusions, infections, or other permanent visual impairment. The potential advantages of this procedure are that it does not involve manipulation of the conjunctiva, the Tenon capsule, or sclera and therefore preserves the option for subsequent standard filtering surgery if necessary. There is also no risk of bleb-related complications such as leaks, blebitis, endophthalmitis, dellen, and dysesthesia, as there is no bleb formation. Hypotony has been rare, most likely if an inadvertent cyclodialysis occurs. The IOP-lowering effect after several months appears to stabilize in the mid-teens through 5 years of follow-up (n = 10).9 After Trabectome, the majority of eyes require a reduced number of IOP-lowering medications. As a brief update on Trabectome, data now include IOP and medication outcomes on a total of 2,012 surgeries, including 1,228 Trabectome-only (Figures 1 and 2) and 687 combined Trabectome-phacoemulsification surgeries (Figures 3 and 4), continuing to demonstrate that clinically significant IOP and adjuvant medication reliance decrease follow these surgeries. Updated survival analyses for these two groups are also encouraging, especially for the combined cases (Figures 5 and 6).

CANALOPLASTY

Canaloplasty is another new angle surgical procedure that involves conjunctival incision, fashioning a trabeculectomy-like scleral flap and a smaller deeper flap, which is excised to expose Schlemm’s canal, thus allowing direct access of aqueous to the collector channels. This theoretically bypasses the main site of resistance to aqueous outflow and reestablishes the natural drainage passageway out of the eye. Briefly, a 1.7-mm clear corneal incision is made temporally, through which the electrosurgical handpiece is inserted and advanced to the nasal angle under gonioscopic visualization. The tip of the device is inserted into Schlemm’s canal through the trabecular meshwork, and the cautery is then activated via a foot pedal. The handpiece is advanced while cautery is activated to an arc of the meshwork, exposing the back wall of Schlemm’s canal, usually for 90° to 120°. A modified Swan-Jacob goniolens (Ocular Instruments Inc, Bellevue, Washington) was developed for this procedure. The handpiece is then removed, and a single 10-0 suture is placed through the incision. This procedure has also been combined with microincisional phacoemulsification, and the IOP-lowering effect of the combined procedure has been previously reported to be 30% at 1 year in a study of 304 consecutive eyes.8,9

The main complication reported in the use of the Trabectome is transient hyphema (79% to 100%). There have been no reports of choroidal effusions, infections, or other permanent visual impairment. The potential advantages of this procedure are that it does not involve manipulation of the conjunctiva, the Tenon capsule, or sclera and therefore preserves the option for subsequent standard filtering surgery if necessary. There is also no risk of bleb-related complications such as leaks, blebitis, endophthalmitis, dellen, and dysesthesia, as there is no bleb formation. Hypotony has been rare, most likely if an inadvertent cyclodialysis occurs. The IOP-lowering effect after several months appears to stabilize in the mid-teens through 5 years of follow-up (n = 10).9 After Trabectome, the majority of eyes require a reduced number of IOP-lowering medications. As a brief update on Trabectome, data now include IOP and medication outcomes on a total of 2,012 surgeries, including 1,228 Trabectome-only (Figures 1 and 2) and 687 combined Trabectome-phacoemulsification surgeries (Figures 3 and 4), continuing to demonstrate that clinically significant IOP and adjuvant medication reliance decrease follow these surgeries. Updated survival analyses for these two groups are also encouraging, especially for the combined cases (Figures 5 and 6).

DISCUSSION

Trabeculectomy enhanced with antimetabolite is the current “gold standard” to which all other surgical procedures are customarily compared. Many studies have repeatedly established that complication rates after trabeculectomy, such as wound leaks, hypotony, and blebitis, are relatively high and frequently associated with permanent visual disability. It has been reported that the risk of late-onset endophthalmitis in mitomycin C–treated trabeculectomies is approximately 1% per patient year.1 Severe loss of central vision has been reported to occur in 6% of eyes after trabeculectomy.2

Tube shunt implants have traditionally been reserved for patients who are deemed at high risk for failure with trabeculectomy, including neovascular or uveitic glucomas, and patients who had previously failed trabeculectomy. The recently published TVT study has altered the thinking of many glaucoma surgeons, who have generally expressed surprise that the Baerveldt glaucoma implant can result in IOP lowering comparable to trabeculectomy when supplemented with IOP-lowering medications, while maintaining a lower risk profile.3 Nevertheless, both trabeculectomy and tube shunt implants remain labor-intensive in the postoperative period and can be accompanied by serious complications. It is for these reasons that newer devices and procedures are being developed in an attempt to improve patient outcomes.

The utility of these newer technologies remains unclear in the most at-risk patient population with advanced cupping and visual field loss. Both procedures report minimal complication rates, the most common of which is transient hyphema. Canaloplasty is more
complex than Trabectome and relies on extensive manipulation of the conjunctiva, sclera, and the Tenon capsule, whereas the Trabectome procedure does not require conjunctival or scleral dissection.

Comparing the reported results of these new procedures across case series is complicated by the lack of a common definition of success or failure and complications. Arbitrary definitions of success may result in misleading comparisons and opportunities for investigators to favorably adjust data analysis to present results that may affect the perceptions of readers. The establishment of a consensus in the glaucoma community on standard definitions of success and failure will greatly aid evaluation of outcomes and minimize the current variable methods by which data are presented. Other desirable issues for ongoing reports on these new angle procedures would include standardized reporting of previous surgeries, such as laser trabeculoplasty, and previous failed filtering operations. Analyses to date indicate that prior laser trabecucloplasty or failed filtering surgery has minimal impact on Trabectome outcomes (S. Vold et al, American Glaucoma Society, San Diego, March 5-8, 2008, poster presentation, and D. Minckler et al, American Glaucoma Society, San Diego, March 5-8, 2008, poster presentation).

In conclusion, trabecuclome remains the most effective IOP-lowering procedure to date; however, it is accompanied by the highest risk of severe complications. Trabectome and canaloplasty require the use of specialized expensive equipment, implants, or devices that may not be readily available in many parts of the world. Trabecuclome remains relatively inexpensive and is accessible to any trained ophthalmic surgeon. Current concepts regarding estimating and striving for a pressure goal proportional to the extent of optic nerve damage would generally require lower IOPs in advanced glaucoma than either Trabectome or canaloplasty regularly achieve. However, normalizing IOP may be adequate for many patients. Trabectome has special appeal, as it is less invasive than canoplasty or trabeclome and has no risk of bleb development. Neither Trabectome nor canoplasty require antifibrotic agents, eliminating the associated risks with mitomycin C and 5-fluorouracil. Both of these new procedures have promise for application early in the glaucoma damage sequence in patients who cannot tolerate or adhere to medications or who fail laser trabecuclomelopy.

ACKNOWLEDGMENTS

Funding/Support: Supported in part by the Research to Prevent Blindness Challenge Grant and by grant EY03040 from the National Institutes of Health/National Eye Institute, Bethesda, Maryland.

Financial Disclosures: Dr Mosaed and Dr Minckler are paid consultants for NeoMedix, the patent holder and manufacturer of Trabectome.

Author Contributions: Design and conduct of the study (S.M., D.M.); Collection, management, analysis, and interpretation of data (S.M., D.M., L.D.); Preparation, review, and approval of the manuscript (S.M., D.M.).

Conformity With Author Information: Data were collected with local Institutional Review Board approval, in accordance with the Declaration of Helsinki and the Health Insurance Portability and Accountability Act.

REFERENCES


Outcomes of Newer and Older Glaucoma Surgery

PEER DISCUSSION

DR. ANNE L. COLEMAN: Mosaed and co-authors have evaluated success rates, intraocular pressure (IOP) reductions, adjunctive medication use, and complications of two new glaucoma surgeries, the Trabectome® and iScience Interventional™ (canaloplasty), and two more well-established procedures, trabeculectomy and aqueous shunts. The authors appropriately started this analysis with a careful literature review of relevant peer-reviewed publications. Because there was only one relevant study on the Trabectome® and one other relevant study on iScience Interventional™ there was not enough literature on these procedures to perform a formal meta-analysis. Regarding trabeculectomy and aqueous shunts, the findings from the Tube versus Trabeculectomy Study (TVT) were used for this analysis. Because the literature on trabeculectomy and aqueous shunts is extensive, there might be value in combining study results in a formal meta-analysis. However, the retrospective comparison of studies can be fraught with limitations, such as that study populations typically differ between manuscripts, underscoring the importance of checking the comparability of study populations based on their covariates. In addition, definitions of failure and complications can differ among studies. For a case in the Trabectome® study to be characterized as a “failure”, the case would need to have IOP > 21mmHg, post-baseline IOP values that fail to reach a level at least 20% below the baseline IOP on two consecutive visits, and no additional glaucoma surgery. This framework is not the same as the approach to classifying cases as failures in the TVT study, where multiple potential reflections of poor clinical outcomes are joined by the conjunction “or” rather than “and”. With the definition used in the Trabectome® Study subjects with preoperative IOPs less than 21 mmHg could be automatic successes even if their only reflection of success is that their IOP did not rise above 21 mmHg. This is in sharp contrast to the iScience intervention study where Kaplan-Meier success rates were not reported. Although the 95% one-year success rate of the Trabectome® in conjunction with phacoemulsification appears to be better than that of trabeculectomy alone, with an 86.5% success rate, a more convincing determination will need to await a randomized, controlled clinical trial, which can be expected to mitigate concerns about possible hidden confounders, subtle distinctions in the case-mix across treatment arms, and differences in the characterization of failure, any of which could be influencing the results.

ACKNOWLEDGMENTS

Funding/Support: None

Financial Disclosure: None

REFERENCES


DR. ROBERT L. STAMPER: I would like to congratulate the authors. I certainly agree with the idea of moving forward with standardized definitions for success, failure, and long-term follow-up. One concern I have about this study is that there are four different procedures and, when most of the data for the studies that you reviewed were collected, the procedures had different indications. One tended to save the Baerveldt type surgery for end-stage or late-stage glaucoma, trabeculectomies were used in the middle stages of the disease, and I am not sure exactly what the indications for the canaloplasty were, but it was often done in association with cataract surgery. The Trabectome® tended to be used in earlier stage glaucoma, so that makes comparing the outcomes in these different groups difficult. I neglected to mention that I do have a conflict. I have served as a consultant to iScience Interventional™ in the past.

DR. M. EDWARD WILSON: No conflict of interest. I would just like for someone to explain to me how the iScience Interventional™ canaloplasty works. How does it promote an increased drainage? It does not make any sense and perhaps the mechanism of action is not known. Is this just a constant inflammatory focus within the canal of Schlemm that continually tickles the trabecular meshwork or is there some better explanation?

Dr. Sameh Mosaed: It is very difficult to compare apples and oranges. When you are comparing a double-blind randomized study to an observational case series, obviously the results in the inclusion/exclusion criteria and the follow-up are going to be very different. We used what was available in the literature review and we were limited by what is available right now. The purpose of the study was to determine whether or not these newer technologies really compare favorably to our standard procedures. We still have a standard to which we compare all glaucoma procedures, and that is trabeculectomy. The iScience Interventional™ canaloplasty study by Lewis and colleagues is a randomized, multicenter, international study, with a site in Germany and several sites in the United States. It is an ongoing randomized study, and they reported the two year outcomes in this month’s Journal of Cataract and Refractive Surgery. The report essentially maintains the same types of outcomes, showing a sustained outcome at two years. Your points are very well taken.
Regarding Dr. Stamper’s comments about whether or not the indications for enrollment and the selection was different, the indications for enrolling the subjects in the iScience Interventional™ canaloplasty study, the Trabectome® data, and the Tube versus Trabeculectomy Study were fairly similar: uncontrolled intraocular pressure on maximum tolerated medical therapy. The majority of subjects in these studies had prior procedures, such as laser interventions and the baseline characteristics of the subjects, such as mean age at enrollment and race were very similar. There can be some comparisons drawn.

How does iScience Interventional™ canaloplasty work? I am really not sure to be honest with you. I do not think anyone really is certain, but there are some theories. One suggests that this is a stenting procedure might put the trabecular meshwork on stretch and allow improved filtration. Perhaps the same type of mechanism might be operational in trabeculectomy. There may be an inflammatory aspect and the recruitment of macrophages could result in cleaning up of the angle structures. Evaluating the data suggests to me that there might also be some microperforation or entry into the anterior chamber as a microtrabeculectomy. It is very difficult to perform these procedures. The iScience Interventional™ canaloplasty requires a very high skill level. The fact that 12% of subjects developed a bleb during the follow-up period indicates that many of these procedures may have involved entry of the anterior chamber and developed a filtration component. Thank you.